Several studies are currently underway to help increase our understanding of the causes of diabetes and its complications, and to develop better strategies to prevent and manage its complications. Our DECRU also offers our patients and other volunteers the opportunity to participate in state-of-the-art phase I, II, III, and IV clinical trials with investigational medications for the treatment of diabetes and related metabolic disorders.
For further information about our DECRU and our clinical trials please contact:
Melanie Smith, RN
Research Nurse, Diabetes & Endocrine Clinical Research Unit
510 20th Street South/ FOT 702
Birmingham, AL 35294
Phone 205-934-4112; Fax 205-934-4379
Studies Open for Enrollment
Type I Diabetes Studies
- A Phase III, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Clinical Efficacy and Safety of DiaPep277® in Newly Diagnosed Type 1 Diabetes Subjects
- An Open label, Randomized Comparison of the Immunogenicity Safety of Wockhardt’s Insulin Analogue Glargine (Glaritus) with Sanofi Aventis’ Insulin Analogue Glargine (Lantus) in Type 1 Diabetic Patients
Type II Diabetes Studies
- A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients with Type 2 Diabetes
- A 24-week, multicenter, international, randomized (1:1), parallel-group, open-label comparative study of insulin glargine versus liraglutide in insulin-naïve patients with Type 2 diabetes treated with oral agents and not adequately controlled, followed by a 24-week extension period with insulin glargine for patients not adequately controlled with liraglutide
- A randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier® Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Metformin and/or SUAnti- Diabetes Agents
- A randomized Clinical Trial of Subcutaneous Analog Basal Bolus Therapy Versus Sliding Scale Human Regular Insulin in the Hospital Management of Hyperglycemia in Non-Critically Ill Patients without Known History of Diabetes
Other Endocrinology Studies
- Changes in Bone Turnover with Increased Incretin Hormone Exposure
- Changes in Bone Turnover with Exposure to a GLP-1 Receptor Agonist
- Bone Mineral Density in HIV+ Patients Recently Started on Antiretroviral Therapy (ART)
- A Blinded Placebo Controlled Single Ascending Dose Phase 1 for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Subcutaneous Administration of VRS-317 in Adults with Growth Hormone Deficiency
